Mouse models of intestinal cancer

Journal of Pathology

Volumn 238, Issue 2, 2016, Pages 141-151

  Jackstadt, Rene ^a   Sansom, Owen J ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Adenomatous polyposis coli; Colorectal cancer; Crc; GEMM; Invasion; Metastasis; organoids; Transplantation

Indexed keywords

APC PROTEIN;

ADENOMA; CANCER MORTALITY; CARCINOGENESIS; DISEASE COURSE; GENE DELETION; GENE EXPRESSION; GENETIC ENGINEERING; GENETICALLY ENGINEERED MOUSE STRAIN; IN VIVO STUDY; INTESTINE CANCER; METASTASIS; MOUSE MODEL; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; RAT MODEL; REVIEW; SPATIOTEMPORAL ANALYSIS; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; COLON POLYPOSIS; COLORECTAL TUMOR; DEFICIENCY; DISEASE MODEL; FORECASTING; GENETICS; HUMAN; MOUSE; MUTATION; PROCEDURES; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CARCINOGENESIS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FORECASTING; GENES, APC; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION;

EID: 84951265920     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4645     Document Type: Review

References (128)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clinic 2011; 61: 69-90.
2. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. Sottoriva A, Kang H, Ma Z, et al., A Big Bang model of human colorectal tumor growth. Nat Genet 2015; 47: 209-216.
4. Morin PJ, Sparks AB, Korinek V, et al., Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275: 1787-1790.
5. Bienz M, Clevers H,. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
6. Fearon ER,. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
7. Hedrick L, Cho KR, Fearon ER, et al., The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994; 8: 1174-1183.
8. Fearon ER, Cho KR, Nigro JM, et al., Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
9. Drost J, van Jaarsveld RH, Ponsioen B, et al., Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015; 521: 43-47.
10. Rajagopalan H, Nowak MA, Vogelstein B, et al., The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; 3: 695-701.
11. Pino MS, Chung DC,. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138: 2059-2072.
12. Vogelstein B, Papadopoulos N, Velculescu VE, et al., Cancer genome landscapes. Science 2013; 339: 1546-1558.
13. Cancer Genome Atlas,. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
14. March HN, Rust AG, Wright NA, et al., Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 2011; 43: 1202-1209.
15. Markowitz S, Wang J, Myeroff L, et al., Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338.
16. Scherer SJ, Avdievich E, Edelmann W,. Functional consequences of DNA mismatch repair missense mutations in murine models and their impact on cancer predisposition. Biochem Soc Trans 2005; 33: 689-693.
17. Wei K, Kucherlapati R, Edelmann W,. Mouse models for human DNA mismatch-repair gene defects. Trends Mol Med 2002; 8: 346-353.
18. Wojciechowicz K, Cantelli E, Van Gerwen B, et al., Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. Gastroenterology 2014; 147: 1064-1072, e1065.
19. Kelderman S, Schumacher TN, Kvistborg P,. Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell 2015; 28: 11-13.
20. Wang K, Karin M,. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res 2015; 128: 173-196.
21. Quante M, Varga J, Wang TC, et al., The gastrointestinal tumor microenvironment. Gastroenterology 2013; 145: 63-78.
22. Groden J, Thliveris A, Samowitz W, et al., Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
23. Rustgi AK,. The genetics of hereditary colon cancer. Genes Dev 2007; 21: 2525-2538.
24. Moser AR, Mattes EM, Dove WF, et al., ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA 1993; 90: 8977-8981.
25. Moser AR, Pitot HC, Dove WF,. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-324.
26. Hull MA, Booth JK, Tisbury A, et al., Cyclo-oxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-1405.
27. Williams CS, Luongo C, Radhika A, et al., Elevated cyclo-oxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-1140.
28. Baron JA, Cole BF, Sandler RS, et al., A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
29. Sandler RS, Halabi S, Baron JA, et al., A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
30. Steinbach G, Lynch PM, Phillips RK, et al., The effect of celecoxib, a cyclo-oxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
31. Dietrich WF, Lander ES, Smith JS, et al., Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993; 75: 631-639.
32. MacPhee M, Chepenik KP, Liddell RA, et al., The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995; 81: 957-966.
33. McCart AE, Vickaryous NK, Silver A,. Apc mice: models, modifiers and mutants. Pathol Res Pract 2008; 204: 479-490.
34. Young M, Ordonez L, Clarke AR,. What are the best routes to effectively model human colorectal cancer? Mol Oncol 2013; 7: 178-189.
35. + mice. Genetics 1996; 144: 1769-1776.
36. Moser AR, Dove WF, Roth KA, et al., The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 1992; 116: 1517-1526.
37. + mice. Carcinogenesis 2012; 33: 1231-1238.
38. Mai V, Colbert LH, Berrigan D, et al., Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms. Cancer Res 2003; 63: 1752-1755.
39. Pollard P, Deheragoda M, Segditsas S, et al., The Apc 1322 T mouse develops severe polyposis associated with submaximal nuclear β-catenin expression. Gastroenterology 2009; 136: 2204-2213, e2201-2213.
40. Cheung AF, Carter AM, Kostova KK, et al., Complete deletion of Apc results in severe polyposis in mice. Oncogene 2010; 29: 1857-1864.
41. Lewis A, Segditsas S, Deheragoda M, et al., Severe polyposis in Apc (1322 T) mice is associated with submaximal Wnt signalling and increased expression of the stem cell marker Lgr5. Gut 2010; 59: 1680-1686.
42. Fodde R, Edelmann W, Yang K, et al., A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994; 91: 8969-8973.
43. Nagy A., Cre recombinase: the universal reagent for genome tailoring. Genesis 2000; 26: 99-109.
44. Sansom OJ, Meniel V, Wilkins JA, et al., Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA 2006; 103: 14122-14127.
45. Jackson EL, Willis N, Mercer K, et al., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
46. Hayashi S, McMahon AP,. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002; 244: 305-318.
47. Akyol A, Hinoi T, Feng Y, et al., Generating somatic mosaicism with a Cre recombinase-microsatellite sequence transgene. Nat Methods 2008; 5: 231-233.
48. Shibata H, Toyama K, Shioya H, et al., Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 1997; 278: 120-123.
49. Sansom OJ, Reed KR, Hayes AJ, et al., Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-1390.
50. Andreu P, Colnot S, Godard C, et al., Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. Development 2005; 132: 1443-1451.
51. Sansom OJ, Meniel VS, Muncan V, et al., Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446: 676-679.
52. Athineos D, Sansom OJ,. Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine. Oncogene 2010; 29: 2585-2590.
53. Ashton GH, Morton JP, Myant K, et al., Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell 2010; 19: 259-269.
54. Myant KB, Cammareri P, McGhee EJ, et al., ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013; 12: 761-773.
55. Cole AM, Myant K, Reed KR, et al., Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 2010; 70: 8149-8158.
56. Feng Y, Sentani K, Wiese A, et al., Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. Am J Pathol 2013; 183: 493-503.
57. Malaterre J, Carpinelli M, Ernst M, et al., c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc Natl Acad Sci USA 2007; 104: 3829-3834.
58. Hinoi T, Akyol A, Theisen BK, et al., Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9721-9730.
59. Robanus-Maandag EC, Koelink PJ, Breukel C, et al., A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis 2010; 31: 946-952.
60. Barker N, van Es JH, Kuipers J, et al., Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
61. de Lau W, Barker N, Low TY, et al., Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011; 476: 293-297.
62. Barker N, Ridgway RA, van Es JH, et al., Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608-611.
63. Powell AE, Vlacich G, Zhao ZY, et al., Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. Am J Physiol Gastrointest Liver Physiol 2014; 307: G16-23.
64. Sangiorgi E, Capecchi MR,. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40: 915-920.
65. Zhu L, Gibson P, Currle DS, et al., Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457: 603-607.
66. Schwitalla S, Fingerle AA, Cammareri P, et al., Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem cell-like properties. Cell 2013; 152: 25-38.
67. Westphalen CB, Asfaha S, Hayakawa Y, et al., Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest 2014; 124: 1283-1295.
68. Shih IM, Wang TL, Traverso G, et al., Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 2001; 98: 2640-2645.
69. Jarde T, Evans RJ, McQuillan KL, et al., In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-OΔN89β-catenin system. Oncogene 2013; 32: 883-893.
70. Dow LE, Nasr Z, Saborowski M, et al., Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PloS One 2014; 9: e95236.
71. Friedl P, Wolf K,. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374.
72. Thiery JP, Acloque H, Huang RY, et al., Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
73. Tam WL, Weinberg RA,. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19: 1438-1449.
74. Loboda A, Nebozhyn MV, Watters JW, et al., EMT is the dominant program in human colon cancer. BMC Med Genom 2011; 4: 9.
75. Janssen KP, Alberici P, Fsihi H, et al., APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131: 1096-1109.
76. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
77. Marsh V, Winton DJ, Williams GT, et al., Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet 2008; 40: 1436-1444.
78. Leystra AA, Deming DA, Zahm CD, et al., Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res 2012; 72: 2931-2936.
79. Deming DA, Leystra AA, Nettekoven L, et al., PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene 2014; 33: 2245-2254.
80. Hung KE, Maricevich MA, Richard LG, et al., Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 2010; 107: 1565-1570.
81. Munoz NM, Upton M, Rojas A, et al., Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer research 2006; 66: 9837-9844.
82. Takaku K, Oshima M, Miyoshi H, et al., Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998; 92: 645-656.
83. Sodir NM, Chen X, Park R, et al., Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer research 2006; 66: 8430-8438.
84. Hamamoto T, Beppu H, Okada H, et al., Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer research 2002; 62: 5955-5961.
85. Kitamura T, Kometani K, Hashida H, et al., SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nature genetics 2007; 39: 467-475.
86. Clarke AR, Cummings MC, Harrison DJ,. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 1995; 11: 1913-1920.
87. Halberg RB, Katzung DS, Hoff PD, et al., Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci USA 2000; 97: 3461-3466.
88. Muller PA, Caswell PT, Doyle B, et al., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
89. Batlle E, Henderson JT, Beghtel H, et al., β-Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251-263.
90. Batlle E, Bacani J, Begthel H, et al., EphB receptor activity suppresses colorectal cancer progression. Nature 2005; 435: 1126-1130.
91. Fidler IJ,. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metast Rev 1991; 10: 229-243.
92. Sun FX, Sasson AR, Jiang P, et al., An ultra-metastatic model of human colon cancer in nude mice. Clin Exp Metast 1999; 17: 41-48.
93. Kashtan H, Rabau M, Mullen JB, et al., Intra-rectal injection of tumour cells: a novel animal model of rectal cancer. Surg Oncol 1992; 1: 251-256.
94. Cespedes MV, Espina C, Garcia-Cabezas MA, et al., Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007; 170: 1077-1085.
95. Giavazzi R, Jessup JM, Campbell DE, et al., Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 1986; 77: 1303-1308.
96. Bankert RB, Egilmez NK, Hess SD,. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 2001; 22: 386-393.
97. Ogata Y, Hara Y, Akagi Y, et al., Metastatic model of human colon cancer constructed using orthotopic implantation in nude mice. Kurume Med J 1998; 45: 121-125.
98. Calon A, Espinet E, Palomo-Ponce S, et al., Dependency of colorectal cancer on a TGFβ-driven program in stromal cells for metastasis initiation. Cancer Cell 2012; 22: 571-584.
99. Sato T, Vries RG, Snippert HJ, et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
100. Sato T, van Es JH, Snippert HJ, et al., Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 469: 415-418.
101. Koo BK, Stange DE, Sato T, et al., Controlled gene expression in primary Lgr5 organoid cultures. Nat Methods 2012; 9: 81-83.
102. Sato T, Stange DE, Ferrante M, et al., Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.
103. Valeri N, Braconi C, Gasparini P, et al., MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014; 25: 469-483.
104. van Es JH, Clevers H,. Generation and analysis of mouse intestinal tumors and organoids harboring APC and K-Ras mutations. Methods Mol Biol 2015; 1267: 125-144.
105. Huels DJ, Cammareri P, Ridgway RA, et al., Methods to assess Myc function in intestinal homeostasis, regeneration, and tumorigenesis. Methods Mol Biol 2013; 1012: 237-248.
106. Li X, Nadauld L, Ootani A, et al., Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 2014; 20: 769-777.
107. Ran FA, Hsu PD, Lin CY, et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013; 154: 1380-1389.
108. Matano M, Date S, Shimokawa M, et al., Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015; 21: 256-262.
109. van de Wetering M, Francies HE, Francis JM, et al., Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161: 933-945.
110. Huels DJ, Ridgway RA, Radulescu S, et al., E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J 2015; 34: 2321-2333.
111. Rex DK, Ahnen DJ, Baron JA, et al., Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107: 1315-1329; quiz, 1314, 1330.
112. Jass JR,. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130.
113. Rad R, Cadinanos J, Rad L, et al., A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15-29.
114. Davies EJ, Marsh Durban V, Meniel V, et al., PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine. J Pathol 2014; 233: 27-38.
115. Trobridge P, Knoblaugh S, Washington MK, et al., TGFβ receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a β-catenin-independent pathway. Gastroenterology 2009; 136: 1680-1688, e1687.
116. Bennecke M, Kriegl L, Bajbouj M, et al., Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010; 18: 135-146.
117. De Sousa EMF, Wang X, Jansen M, et al., Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618.
118. Radtke F, Clevers H, Riccio O,. From gut homeostasis to cancer. Curr Mol Med 2006; 6: 275-289.
119. Tan Y, Sangfelt O, Spruck C,. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 2008; 271: 1-12.
120. Kim HA, Koo BK, Cho JH, et al., Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 2012; 122: 3248-3259.
121. Chanrion M, Kuperstein I, Barriere C, et al., Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nat Commun 2014; 5: 5005.
122. Schwitalla S, Ziegler PK, Horst D, et al., Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer cell 2013; 23: 93-106.
123. van Boxtel R, Cuppen E,. Generation of genetically modified rodents using random ENU mutagenesis. Methods Mol Biol 2011; 693: 295-308.
124. Mashimo T, Yanagihara K, Tokuda S, et al., An ENU-induced mutant archive for gene targeting in rats. Nat Genet 2008; 40: 514-515.
125. Washington MK, Powell AE, Sullivan R, et al., Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 2013; 144: 705-717.
126. Irving AA, Yoshimi K, Hart ML, et al., The utility of Apc-mutant rats in modeling human colon cancer. Dis Model Mechan 2014; 7: 1215-1225.
127. Flisikowska T, Merkl C, Landmann M, et al., A porcine model of familial adenomatous polyposis. Gastroenterology 2012; 143: 1173-1175, e1171-1177.
128. Faller WJ, Jackson TJ, Knight JR, et al., mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 2015; 517: 497-500.